Yıl: 2022 Cilt: 38 Sayı: 2 Sayfa Aralığı: 99 - 105 Metin Dili: İngilizce DOI: 10.5146/tjpath.2021.01556 İndeks Tarihi: 29-06-2022

The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma

Öz:
Objective: Neuroblastoma (NB) is the most common extracranial solid tumor in children and is responsible for 12% of cancer-related deaths. The status of metastatic disease in the bone marrow (BM) is a predictor of poor outcome. The purpose of this study was to investigate the predictive significance of histopathological examination of BM in NB. Material and Method: The study included 61 cases with archival bone marrow biopsy tissues. The cases were evaluated regarding the percentage of metastatic tissue and its differentiation. Primary tumor slides were also reviewed to perform the Shimada classification based on the differentiation status and mitosis-karyorrhexis index. The patients’ age, gender, NMYC amplification, clinical risk group, and disease outcome were also noted. Results: Of the 61 cases, 17 had BM involvement. Of those, eight cases (47.1%) were refractory NB showing disease relapse. Based on BM examination, five cases (29.4%) were categorized as complete response, seven (41.2%) as progressive disease, three (17.6%) as minimal disease, and two (11.8%) as stable disease. The progressive disease category was significantly related with refractory disease and NMYC amplification along with the high-risk category (p =0.002 and p= 0.003 respectively). Undifferentiated histology and presence of more than 20% of tumor tissue in the BM biopsy at diagnosis were significantly associated with the progressive disease category (p=0.01 and p<0.001, respectively). Conclusion: We conclude that evaluating the percentage of metastatic tumor tissue and tumor differentiation in BM biopsies is of clinical importance in the management of neuroblastoma patients.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GA, Brock PR, Haber M, Park JR, Berthold F. Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer. 2017;123:1095-105.
  • 2. Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, London WB, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. Revisions to the international neuroblastoma response criteria: A consensus statement from the national cancer institute clinical trials planning meeting. J Clin Oncol. 2017;35:2580-7.
  • 3. Morandi F, Corrias MV, Pistoia V. Evaluation of bone marrow as a metastatic site of human neuroblastoma. Ann N Y Acad Sci. 2015;1335:23-31.
  • 4. Teitz T, Inoue M, Valentine MB, Zhu K, Rehg JE, Zhao W, Finkelstein D, Wang YD, Johnson MD, Calabrese C, Rubinstein M, Hakem R, Weiss WA, Lahti JM. Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. Cancer Res. 2013;73:4086-97.
  • 5. Ekmekci S, Olgun N, Özer E. The relationship between apoptotic activity and prognostic factors in neuroblastomas. Turk Patoloji Derg. 2016;32:99-104.
  • 6. Osman J, Galli S, Hanafy M, Tang X, Ahmed A. Identification of novel biomarkers in neuroblastoma associated with the risk for bone marrow metastasis: A pilot study. Clin Transl Oncol. 2013;15:953-8.
  • 7. Yoshino K, Tanabe M, Ohnuma N, Takahashi H. Histopathologic analysis of bone marrow and bone metastasis in murine neuroblastoma. Clin Exp Metastasis. 1996;14:459-65.
  • 8. Jo JH, Ahn SD, Koh M, Kim JH, Lee SW, Song SY, Yoon SM, Kim YS, Kim SS, Park JH, Jung J, Choi EK. Patterns of recurrence after radiation therapy for high-risk neuroblastoma. Radiat Oncol J. 2019;37:224-231.
  • 9. Ulrich H, Ratajczak MZ, Schneider G, Adinolfi E, Orioli E, Ferrazoli EG, Glaser T, Corrêa-Velloso J, Martins PCM, Coutinho F, Santos APJ, Pillat MM, Sack U, Lameu C. Kinin and purine signaling contributes to neuroblastoma metastasis. Front Pharmacol. 2018;9:500.
  • 10. Tian X, Cao Y, Wang J, Yan J, Tian Y, Li Z, Wang H, Duan X, Jin Y, Zhao Q. A single center clinical analysis of children with highrisk neuroblastoma. Oncotarget. 2017;8:30357-68.
  • 11. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK; INRG Task Force. The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol. 2009;27:289-97.
  • 12. Popov A, Druy A, Shorikov E, Verzhbitskaya T, Solodovnikov A, Saveliev L, Tytgat GAM, Tsaur G, Fechina L. Prognostic value of initial bone marrow disease detection by multiparameter flow cytometry in children with neuroblastoma. J Cancer Res Clin Oncol. 2019;145:535-42.
  • 13. Kuroda T, Morikawa N, Matsuoka K, Fujino A, Honna T, Nakagawa A, Kumagai M, Masaki H, Saeki M. Prognostic significance of circulating tumor cells and bone marrow micrometastasis in advanced neuroblastoma. J Pediatr Surg. 2008;43:2182-5.
  • 14. Yue ZX, Huang C, Gao C, Xing TY, Liu SG, Li XJ, Zhao Q, Wang XS, Zhao W, Jin M, Ma XL. MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma. Cancer Cell Int. 2017;17:43.
  • 15. Cai JY, Pan C, Tang YJ, Chen J, Ye QD, Zhou M, Xue H, Tang JY. Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration. Am J Clin Oncol. 2012;35:275-8.
  • 16. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD; INRG Task Force. The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol. 2009;27:298-303.
  • 17. Parsons LN, Gheorghe G, Yan K, Simpson P, Jarzembowski JA. Improving Detection of Metastatic Neuroblastoma in Bone Marrow Core Biopsies: A Proposed Immunohistochemical Approach. Pediatr Dev Pathol. 2016;19:230-6.
  • 18- Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing RB, Matthay KK. Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: A Children’s Cancer Group Study. J Clin Oncol. 2000;18:4067- 76.
  • 19. Russell HV, Golding LA, Suell MN, Nuchtern JG, Strother DR. The role of bone marrow evaluation in the staging of patients with otherwise localized, low-risk neuroblastoma. Pediatr Blood Cancer. 2005;45:916-9.
  • 20. Wang Z, Sun H, Li K, Yao W, Dong K, Ma Y, Zheng S. Prognostic factor analysis of stage 4S neuroblastoma in infant patients: A single center study. J Pediatr Surg. 2019;54:2585-8.
  • 21. Morgenstern DA, London WB, Stephens D, Volchenboum SL, Simon T, Nakagawara A, Shimada H, Schleiermacher G, Matthay KK, Cohn SL, Pearson AD, Irwin MS. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. Eur J Cancer. 2016;65:1-10.
  • 22. Manenq C, Lesesve JF, Dreumont N, Massin F, Salignac S, Mansuy L, Chastagner P, Latger-Cannard V, Broséus J. Combined use of multiparametric flow cytometry and cytomorphology to enhance detection of neuroblastoma metastatic cells in bone marrow. Int J Lab Hematol. 2020;42:52-60.
  • 23. McCarthy LC, Chastain K, Flatt TG, Taboada E, Garola R, Herriges J, Cooley LD, Ahmed AA. Neuroblastoma in Adolescents and Children Older than 10 Years: Unusual Clinicopathologic and Biologic Features. J Pediatr Hematol Oncol. 2019;41:586-95.
APA Ekmekci S, INCE D, Olgun N, Ozer E (2022). The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma. , 99 - 105. 10.5146/tjpath.2021.01556
Chicago Ekmekci Sumeyye,INCE Dilek,Olgun Nur,Ozer Erdener The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma. (2022): 99 - 105. 10.5146/tjpath.2021.01556
MLA Ekmekci Sumeyye,INCE Dilek,Olgun Nur,Ozer Erdener The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma. , 2022, ss.99 - 105. 10.5146/tjpath.2021.01556
AMA Ekmekci S,INCE D,Olgun N,Ozer E The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma. . 2022; 99 - 105. 10.5146/tjpath.2021.01556
Vancouver Ekmekci S,INCE D,Olgun N,Ozer E The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma. . 2022; 99 - 105. 10.5146/tjpath.2021.01556
IEEE Ekmekci S,INCE D,Olgun N,Ozer E "The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma." , ss.99 - 105, 2022. 10.5146/tjpath.2021.01556
ISNAD Ekmekci, Sumeyye vd. "The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma". (2022), 99-105. https://doi.org/10.5146/tjpath.2021.01556
APA Ekmekci S, INCE D, Olgun N, Ozer E (2022). The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma. Türk Patoloji Dergisi, 38(2), 99 - 105. 10.5146/tjpath.2021.01556
Chicago Ekmekci Sumeyye,INCE Dilek,Olgun Nur,Ozer Erdener The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma. Türk Patoloji Dergisi 38, no.2 (2022): 99 - 105. 10.5146/tjpath.2021.01556
MLA Ekmekci Sumeyye,INCE Dilek,Olgun Nur,Ozer Erdener The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma. Türk Patoloji Dergisi, vol.38, no.2, 2022, ss.99 - 105. 10.5146/tjpath.2021.01556
AMA Ekmekci S,INCE D,Olgun N,Ozer E The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma. Türk Patoloji Dergisi. 2022; 38(2): 99 - 105. 10.5146/tjpath.2021.01556
Vancouver Ekmekci S,INCE D,Olgun N,Ozer E The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma. Türk Patoloji Dergisi. 2022; 38(2): 99 - 105. 10.5146/tjpath.2021.01556
IEEE Ekmekci S,INCE D,Olgun N,Ozer E "The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma." Türk Patoloji Dergisi, 38, ss.99 - 105, 2022. 10.5146/tjpath.2021.01556
ISNAD Ekmekci, Sumeyye vd. "The Significance of Histopathologic Assessment in Bone Marrow Disease in Neuroblastoma". Türk Patoloji Dergisi 38/2 (2022), 99-105. https://doi.org/10.5146/tjpath.2021.01556